ANI Pharmaceuticals, Inc. (ANIP)
Price:
89.64 USD
( + 0.51 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Cronos Group Inc.
VALUE SCORE:
8
2nd position
Amphastar Pharmaceuticals, Inc.
VALUE SCORE:
11
The best
Lantheus Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
NEWS
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-09-24 13:46:09ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
5 Biotech Stocks Worth Adding to Your Portfolio Now
zacks.com
2025-09-23 10:25:13The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-09 16:41:58ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Okay. Good Afternoon, everybody.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
zacks.com
2025-09-08 18:11:06ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy?
zacks.com
2025-08-28 13:00:37Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
globenewswire.com
2025-08-25 16:30:00PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team will present at two upcoming investor conferences as follows:
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-08-22 13:46:08ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
zacks.com
2025-08-22 10:15:49ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-11 10:31:30While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:56:48ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-08 09:00:20ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
globenewswire.com
2025-08-08 06:50:00BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
globenewswire.com
2025-08-01 06:50:00PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
zacks.com
2025-07-29 11:05:41ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
globenewswire.com
2025-07-23 06:50:00Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm
No data to display
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-09-24 13:46:09ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
5 Biotech Stocks Worth Adding to Your Portfolio Now
zacks.com
2025-09-23 10:25:13The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
seekingalpha.com
2025-09-09 16:41:58ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Okay. Good Afternoon, everybody.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
zacks.com
2025-09-08 18:11:06ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy?
zacks.com
2025-08-28 13:00:37Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
globenewswire.com
2025-08-25 16:30:00PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team will present at two upcoming investor conferences as follows:
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com
2025-08-22 13:46:08ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
zacks.com
2025-08-22 10:15:49ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2025-08-11 10:31:30While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-08 15:56:48ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
zacks.com
2025-08-08 09:00:20ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
globenewswire.com
2025-08-08 06:50:00BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
globenewswire.com
2025-08-01 06:50:00PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
zacks.com
2025-07-29 11:05:41ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
globenewswire.com
2025-07-23 06:50:00Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm